Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192378 | 0.79 | GPR3 (0.31) | GPR3 | |
| SCHEMBL5702797 | 0.78 | GPR3 (0.33) | GPR3 | |
| SCHEMBL29732984 | 0.78 | KMT2A (0.33) | GPR3 | |
| SCHEMBL7863731 | 0.78 | GPR3 (0.38) | GPR3HTR2A | |
| SCHEMBL5473851 | 0.78 | GPR3 (0.33) | GPR3 | |
| SCHEMBL7632502 | 0.77 | GPR3 (0.31) | GPR3 | |
| SCHEMBL6401816 | 0.76 | HTR6 (0.33) | GPR3HTR2A | |
| Hydrochloric Acid SCHEMBL7609107 | 0.76 | GPR3 (0.36) | GPR3 | |
| Hydrochloric Acid SCHEMBL3192369 | 0.76 | GPR3 (0.32) | GPR3 | |
| Hydrochloric Acid SCHEMBL28436054 | 0.76 | GPR3 (0.32) | GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5208987-A | — | — | None | — | — | JP | disclosed |
| US-20230106731-A1 | INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES | SPECTRUM PHARMACEUTICALS, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| JP-H05208987-A | HAFNIUM COMPOUND HAVING ASYMMETRIC LIGAND AND CATALYST COMPONENT | SHOWA DENKO KK | 1993-08-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106731-A1 | INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES | ERBB2, EGFR, ERBB3 | GPR3 1639/4885HTR2A 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.